Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
Uro-Oncology
Related content
Uro-Oncology
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
N Engl J Med
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, VISION Investigators.
doi: 10.1056/NEJMoa2107322
Uro-Oncology
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Eur Urol
Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C, Morgenstern A, Eiber M
doi: 10.1016/j.eururo.2020.11.013
Uro-Oncology
Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer
Prostate.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M
doi: 10.1002/pros.23919.
Uro-Oncology
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer
Prostate Cancer Prostatic Dis
Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N
doi: 10.1038/s41391-021-00424-2
Uro-Oncology
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Prostate.
Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH
doi: 10.1002/pros.23954.
Uro-Oncology
The value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapy
Prostate.
Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R, Essler M, Holdenrieder S, Ahmadzadehfar H
doi: 10.1002/pros.23912.
COMMENTED
Uro-Oncology
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
★ 3
Recommended by
Alexander Meisel, Faculty Member
Eur Urol.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
doi: 10.1016/j.eururo.2019.09.019.
Uro-Oncology
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data
Prostate Cancer Prostatic Dis
Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK
doi: 10.1038/s41391-021-00326-3
Uro-OncologyFurther Publications Urology
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
Eur Urol
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ
doi: 10.1016/j.eururo.2021.09.030